Hyperuricemia

Allena Pharmaceuticals Inc. announced its ALLN-346 Phase 2a Study 202 examining ALLN-346 treatment in patients with gout and advanced chronic kidney disease has completed enrollment for cohorts A and B.

Although allopurinol, febuxostat and pegloticase are still relied on to do the heavy lifting in lowering urate for patients with gout, an “influx of newer agents” may help expand effective disease management, according to a presenter here.

Although the DASH diet can lower gout risk in women regardless of genetics, nonadherence can result in a greater risk in those with a higher predisposition for elevated serum urate, according to a speaker at the EULAR 2021 Congress.

The Dietary Approaches to Stop Hypertension — or DASH — diet successfully reduces serum urate, particularly among those with hyperuricemia, according to data published in Arthritis & Rheumatology.

While the 2020 American College of Rheumatology guidelines for gout management are a step up from the 2012 iteration, gaps remain in management of the disease, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.

ATLANTA — Gout is associated with an increased risk for cardiovascular disease, as calculated via population-level cardiovascular risk equations, according to data presented at ACR/ARP 2019.

ATLANTA — The 2019 ACR gout guidelines call for treating patients to a target serum urate level of 6 mg/dL, a marked departure from the 2012 document, according to speakers at ACR/ARP 2019.

SAN DIEGO — Prolonged adherence to urate-lowering therapies is critical for patients to manage gout, yet only a fraction of patients receive the appropriate therapy, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

Children who are obese or overweight may be at higher risk for kidney alterations and kidney disease risk factors, a recently published cross-sectional study suggests.

ORLANDO — Patients with uncontrolled gout are more likely to develop chronic kidney disease, diabetes and heart disease compared with those with controlled disease, according to a poster presentation at the 2019 Rheumatology Nurses Society Annual Conference.